Free shipping on all orders over $ 500

Cemiplimab

Cat. No. M15101

All AbMole products are for research use only, cannot be used for human consumption.

Cemiplimab Structure
Synonym:

Libtayo; REGN-2810; cemiplimab-rwlc

Size Price Availability
1mg USD 430  USD430 4-7 Days
5mg USD 1290  USD1290 4-7 Days
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
  • Purity: >99%, Endotoxin < 2 EU/mg
  • COA
  • MSDS
Biological Activity

Cemiplimab (Libtayo) is a human monoclonal antibody injected intravenously that targets programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands PD-1 and PD-L2. Source: HEK293

In vivo: Cemiplimab (REGN2810) binds to the humanized PD-1 receptor and inhibits tumor growth in MC38 mice in human PD-1 knockout mice. REGN2810 has a high affinity for cynomolgus monkey PD-1, and its pharmacokinetics and toxicology were studied in cynomolgus monkey. High dose REGN2810 was well tolerated without adverse immune-related effects. In vitro: In cell-based assays, REGN2810 reversed PD-1-dependent attenuation of T-cell receptor signaling and enhanced human primary T-cell responses.

Chemical Information
CAS Number 1801342-60-8
Storage 4°C, protect from light, dry, sealed
References

[1] Krishnansu S Tewari, et al. N Engl J Med. Survival with Cemiplimab in Recurrent Cervical Cancer

[2] Alexander J Stratigos, et al. Lancet Oncol. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

[3] Ahmet Sezer, et al. Lancet. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

[4] Arnold Lee, et al. Drugs. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma

[5] Michael R Migden, et al. N Engl J Med. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Related PD-1/PD-L1 Products
SL-279252

SL-279252 (PD1-Fc-OX40L) is a hexameric, bi-functional fusion protein with an ECD of PD-1 (70 pM affinity to PD-L1) linked to the ECD of OX40L (324 pM affinity for OX40) through an Fc linker. SL-279252 exhibited linear PK at doses up to 3.0 mg/kg, and a greater than proportional increase in AUC was observed at 6.0 mg/kg suggesting potential receptor saturation. The preliminary half-life is approximately 23 hours.

Rosnilimab

Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state.

Recombinant Anti-Mouse PD1 mAb

Recombinant Anti-Mouse PD1 mAb is a recombinant monoclonal antibody against the mouse PD1 protein, with the antibody isoform Mouse lgG1/lambda. the antibody efficiently binds to the mPD1 protein on the cell surface and significantly inhibits tumor growth in a mouse tumor model transplanted with MC38 cells. the antibody is used to detect the presence of the mouse PD1 protein on the cell surface of the cell. the antibody is used to detect the presence of the mouse PD1 protein on the cell surface of the cell.

Erfonrilimab

Erfonrilimab is a humanized single-domain bispecific antibody-Fc fusion protein (VH-VH-h-CH2-CH3 dimer) targeting the immune checkpoints PD-L1 and CTLA-4.

Benmelstobart

Benmelstobart is an anti-PD-L1 humanized IgG1ҡ monoclonal antibody that can be used for tumor-related studies.

  Catalog
Abmole Inhibitor Catalog




Keywords: Cemiplimab, Libtayo; REGN-2810; cemiplimab-rwlc supplier, PD-1/PD-L1, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.